시장보고서
상품코드
1309716

세계의 POC 분자진단 시장 규모, 점유율, 산업 동향 분석 보고서 : 제품 및 서비스별, 최종 사용자별, 기술별, 용도별, 지역별 전망과 예측(2023-2030년)

Global Point of Care Molecular Diagnostics Market Size, Share & Industry Trends Analysis Report By Product & Service, By End User, By Technology, By Application, By Regional Outlook and Forecast, 2023 - 2030

발행일: | 리서치사: KBV Research | 페이지 정보: 영문 313 Pages | 배송안내 : 즉시배송


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 POC 분자진단(Point of Care Molecular Diagnostics) 시장 규모는 2030년 41억 달러에 이를 전망이며, 10.2%의 CAGR 성장률로 상승할 것으로 예측됩니다.

KBV Cardinal Matrix에 제시된 분석에 따르면 F. Hoffmann-La Roche Ltd.는 시장 선구자입니다. 2020년 6월, Roche는 SpeeDx와 협력하여 Roche Diagonostics는 성병 환자 항생제 내성을 탐지하기 위한 중요하고 고급 도구를 임상의에게 제공할 수 있게 되었습니다. Danaher Corporation, Thermo Fisher Scientific, Inc., Abbott Laboratories 등의 기업은 시장 주요 혁신자입니다.

시장 성장 요인

노인 증가

거의 모든 국가 인구에서 노인 비율이 증가하고 있습니다. WHO는 2030년 세계의 6명 중 1명이 60세 이상이 될 것으로 추정합니다. 이 시점 60세 이상 인구는 14억 명으로 2020년 10억 명 증가합니다. 60세 이상 인구는 2050년 21억 명으로 두 배가 됩니다. 세계의 노화로 호흡기 질환과 장애 유병률이 높아지기 때문에 POC(Point of Care) 분자 진단제 수요가 증가합니다.

분산형 헬스케어 시스템 보급이 시장 확대를 지원합니다.

정확하고 효율적인 치료 선택에 필요한 신속한 진단 결과로, 요점 점검은 환자 중심 건강 관리에 필수적입니다. 만성 질환, 감염 및 만성 질환의 중앙 집중식 포인트 오브 케어 검사 분산 검사로 변화로 인해 환자는 이러한 진단 약물에 쉽게 접근할 수 있습니다. 많은 기업들이 신속한 검사 수요로부터 분산형 시설을 위한 감염증 검사를 개발했습니다. 이러한 신흥국 시장 개척은 시장 성장에 긍정적인 영향을 미칠 것으로 보입니다.

시장 성장 억제 요인

불충분한 상환 상황

불충분한 진료 보상이 POC 분자진단 시장 확대 장벽이 됩니다. 진단 기업이 발생하는 주요 어려움 중 일부는 메디케어 및 민간 의료 보험 회사로부터 진단 검사를 상환받을 수 있습니다. 2018년 미국 메디케어는 포인트 오브 케어 분자 분석 등 일부 체외 진단(IVD) 검사 상환 방법을 변경했습니다. 다양한 이익단체가 검사 가치를 높이고 적절한 금액으로 상환을 창출하는 설득력 있는 로비 역할을 할 수 있습니다. 포인트 오브 케어 분자 검사 시장은 이러한 변수가 마이너스에 작용할 것으로 예측됩니다.

제품 및 서비스 전망

제품 및 서비스에 따라 시장은 분석 및 키트, 장비 및 분석 장비, 소프트웨어 및 서비스로 구분됩니다. 2022년 기기, 분석장치 부문시장 큰 매출 점유율을 획득했습니다. 혈장, 소변, 객담, 면봉 등 샘플을 분자 분석기를 사용하여 검사합니다. 대부분 분자 시스템은 결핵, 클라미디아, HIV-1, HBV, HCV와 같은 광범위한 검사 파라미터를 제공합니다. 그 결과, 결핵이나 호흡기 질환 등에 걸리는 사람이 늘어남에 따라 기기 및 분석 장치 시장은 확대됩니다.

최종 사용자별 전망

최종 사용자별로는 의원, 병원, ICU, 연구기관 등으로 분류됩니다. 2022년 진료소가 시장 가장 큰 수익 점유율을 기록했습니다. 30분 이내에 신속한 결과를 얻을 수 있기 때문에 POC 분자 검사 및 키트 및 시스템은 이러한 상황 자주 사용됩니다. 이를 통해 신속한 진단이 가능하며 의사는 환자 상태를 신속하게 판단하고 추적할 수 있습니다.

기술 전망

기술별로는 시장은 RT-PCR, 등온 핵산 증폭 기술(INAAT), 기타 기술로 나뉩니다. INAAT 분야는 2022년 시장 현저한 수익 점유율을 기록했습니다. 만성 질환 유병률 상승과 노화 결과, INAAT(Isothermal Nucleic Acid Amplification Technology)는 성장할 것으로 예측됩니다. PCR보다 INAAT 채용이 증가하고 합리적인 가격으로 효율적인 진단 절차 수요가 증가하고 있는 것도 이 부문 확대를 뒷받침하는 주요 요인입니다.

용도, 전망

용도별 시장은 호흡기 질환, 성 감염증, 병원 감염증, 간염, 암, 소화기 질환 등으로 나뉘며 2022년 호흡기 질환 분야가 가장 높은 수익 점유율을 획득하여 시장을 독점했습니다. 감염증 빈도 증가, 이러한 질병 조기 진단 및 특정 요구 증가가 시장 부문 확대를 뒷받침하는 주요 요인입니다.

지역별 전망

지역별로 시장은 북미, 유럽, 아시아태평양, LAMEA로 나뉩니다. 2022년 북미가 가장 큰 수익 점유율로 시장을 선도했습니다. 시장 확대에 영향을 미치는 주요 요인 중 하나는 지역 건강 관리 시스템의 악성 종양과 감염 부하입니다. 이 지역 POC 분자 진단 시장 개척을 뒷받침할 것으로 예상되는 그 밖 요인으로는 정비된 헬스 케어 인프라 존재나 정교한 기술 수용이 진행되고 있는 것 등을 들 수 있습니다.

목차

제1장 시장 범위와 조사 방법

  • 시장 정의
  • 목적
  • 시장 범위
  • 세분화
  • 조사 방법

제2장 시장 주요 요약

  • 소개
    • 주요 요약
      • 시장구성과 시나리오
  • 시장에 영향을 미치는 주요 요인
    • 시장 성장 촉진 요인
    • 시장 성장 억제 요인

제3장 경쟁 분석

  • KBV Cardinal Matrix
  • 최근 업계 전체 전략 전개
    • 제휴, 협정 및 계약
    • 제품 출시 및 제품 확대
    • 인수와 합병
  • 주요 성공 전략
    • 주요 전략

제4장 세계의 POC 분자진단 시장 : 제품과 서비스별

  • 세계의 분석 및 키트 시장 : 지역별
  • 세계의 계측기 및 분석 장치 시장 : 지역별
  • 세계의 소프트웨어 및 서비스 시장 : 지역별

제5장 세계의 POC 분자진단 시장 : 최종 사용자별

  • 세계의 의사 오피스 시장 : 지역별
  • 세계의 병원 및 ICU 시장 : 지역별
  • 세계의 조사기관 시장 : 지역별
  • 세계의 기타 시장 : 지역별

제6장 세계의 POC 분자진단 시장 : 기술별

  • 세계의 RT-PCR 시장 : 지역별
  • 세계의 등온 핵산 증폭 기술(INAAT) 시장 : 지역별
  • 세계의 기타 시장 : 지역별

제7장 세계의 POC 분자진단 시장 : 용도별

  • 세계의 호흡기 질환 시장 : 지역별
  • 세계의 원내 감염증 시장 : 지역별
  • 세계의 성 감염증 시장 : 지역별
  • 세계의 암 시장 : 지역별
  • 세계의 간염 시장 : 지역별
  • 세계의 소화기 질환 시장 : 지역별
  • 세계의 기타 시장 : 지역별

제8장 세계의 POC 분자진단 시장 : 지역별

  • 북미
    • 북미 시장 : 국가별
      • 미국
      • 캐나다
      • 멕시코
      • 기타 북미
  • 유럽
    • 유럽 시장 : 국가별
      • 독일
      • 영국
      • 프랑스
      • 러시아
      • 스페인
      • 이탈리아
      • 기타 유럽
  • 아시아태평양
    • 아시아태평양 시장 : 국가별
      • 중국
      • 일본
      • 인도
      • 한국
      • 싱가포르
      • 말레이시아
      • 기타 아시아태평양
  • 라틴아메리카, 중동, 아프리카
    • 라틴아메리카, 중동, 아프리카 시장 : 국가별
      • 브라질
      • 아르헨티나
      • 아랍에미리트(UAE)
      • 사우디아라비아
      • 남아프리카
      • 나이지리아
      • 기타 라틴아메리카, 중동, 아프리카

제9장 기업 프로필

  • Abbott Laboratories
  • Bayer AG
  • Thermo Fisher Scientific, Inc
  • F Hoffmann-La Roche Ltd.
  • BioMerieux SA
  • Qiagen NV
  • Danaher Corporation
  • Bio-Rad laboratories, Inc
  • Agilent Technologies, Inc
  • Nova Biomedical Corporation
NJH 23.08.24

The Global Point of Care Molecular Diagnostics Market size is expected to reach $4.1 billion by 2030, rising at a market growth of 10.2% CAGR during the forecast period.

A new generation of POC devices that will change gastrointestinal diagnostic routes has been made possible by recent improvements in analytical methods. Hence, Gastrointestinal Disorders segment accounted for $113.1 million revenue in the market in 2022. About one-third of people in North European and North American populations still have Heliobacter pylori infection, compared to prevalence rates of more than 50% in South and East Europe, South America, and Asia. Immigrants from nations with high H. pylori prevalence continue to have a high prevalence of the stomach virus.

However, the younger generations' lower infection rates imply that the prevalence of H. pylori will continue to fall over the next several decades. The most significant risk factors for H. pylori infection are low socioeconomic situations throughout childhood. A hectic schedule is bringing on gastric ailments, an increase in the style of life, and poor eating habits. In 2018, there were reportedly 4.8 million new cases of cancer and 3.4 million deaths from it, according to the WHO, making up 26% of the burden of cancer incidence globally and 35% of all cancer-related fatalities. As a result, the prevalence of stomach illnesses would spur market expansion throughout the forecasted decade.

The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In March, 2023, QIAGEN N.V. formed a partnership with Servier to develop and validate a real-time in vitro PCR test that can be used to detect IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates. Additionally, In February, 2021, Agilent Technologies formed a partnership with Mammoth Biosciences to offer a simple workflow to address the specific needs of high-throughput clinical testing laboratories.

Based on the Analysis presented in the KBV Cardinal matrix; F. Hoffmann-La Roche Ltd. is the forerunner in the Market. In June, 2020, Roche formed a partnership with SpeeDx to enable Roche Diagnostics to offer clinicians critical and advanced tools for the detection of antibiotic resistance in patients with sexually transmitted infections. Companies such as Danaher Corporation, Thermo Fisher Scientific, Inc., Abbott Laboratories are some of the key innovators in the Market.

Market Growth Factors

An increasing number of older people

In practically every country, the percentage of older adults in the population is growing. WHO estimates that by 2030, 1 in 6 individuals worldwide will be 60 or older. By this point, there will be 1.4 billion people over 60, up from 1 billion in 2020. The number of individuals in the world who are 60 or older will double (to 2.1 billion) by 2050. Over the projection period, there will be an increase in demand for point-of-care molecular diagnostics due to the increased prevalence of respiratory illnesses and disorders among the aging population globally.

Decentralized Healthcare System Proliferation to Support Market Expansion

Due to the fast diagnostic outcomes necessary for precise and efficient treatment choices, point-of-care testing has become essential for patient-centric healthcare. Patients now have easy access to these diagnostics due to a change from centralized point-of-care testing to decentralized testing for chronic, infectious, and chronic conditions. Many players have created infectious disease tests for dispersed sites due to the demand for quick turnaround testing. These developments will favorably impact the growth of the worldwide market.

Market Restraining Factors

Poor reimbursement circumstances

Inadequate reimbursements are a barrier to the point-of-care molecular diagnostics market's expansion. Among the major difficulties diagnostic firms encounter is receiving reimbursement for diagnostic tests from Medicare and commercial health insurers. In 2018, Medicare in the US changed how some in vitro diagnostic (IVD) tests, such as point-of-care molecular assays, were reimbursed. Diverse interest groups could increase a test's worth and serve as a persuasive lobby to generate reimbursement at the right amount. On the market for point-of-care molecular testing, these variables are projected to have a negative effect.

Product and Services Outlook

Based on product & service, the market is segmented into assays & kits, instruments & analyzers, and software & service. In 2022, the instruments & analyzers segment gained a sizable revenue share in the market. Plasma, urine, sputum, and swab samples are tested using molecular analyzers. Most molecular systems provide a broad range of test parameters, including those for TB, Chlamydia, HIV-1, HBV, and HCV. As a result, the equipment and analyzers market is expanding as more people get TBL, respiratory disorders, etc.

End-user Outlook

By end-user, the market is categorized into physicians' offices, hospitals & ICUs, research institutes, and others. In 2022, the physicians' offices segment registered the largest revenue share in market. Due to its ability to provide quick findings within 30 minutes, POC molecular test & kits and systems are often used in these circumstances. This facilitates prompt diagnosis and enables doctors to determine or track a patient's status quickly.

Technology Outlook

By technology, the market is divided into RT-PCR, Isothermal Nucleic Acid Amplification Technology (INAAT), and other technologies. The INAAT segment recorded a remarkable revenue share in the market in 2022. As a result of the rising prevalence of chronic diseases and an aging population, INAAT (Isothermal Nucleic Acid Amplification Technology) is projected to grow. An increase in the adoption of INAAT over PCR and a rise in demand for affordable and efficient diagnostic procedures are other key factors fueling the segment's expansion.

Application Outlook

On the basis of application, the market is bifurcated into respiratory diseases, sexually transmitted diseases, hospital acquired infections, hepatitis, cancer, gastrointestinal disorders, and others. In 2022, the respiratory diseases segment dominated the market by generating the highest revenue share. The increasing frequency of infectious illnesses and the rising need for early diagnosis and identification of these diseases are the main factors fueling the expansion of this market segment.

Regional Outlook

Region wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market with the maximum revenue share. One of the main factors influencing market expansion is the heavy load of malignancies and infectious illnesses on local healthcare systems. Other factors projected to boost the development of the point-of-care molecular diagnostics market in the area include the existence of a well-developed healthcare infrastructure and the rising acceptance of sophisticated technologies.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd., Qiagen N.V., Danaher Corporation, Bio-Rad Laboratories, Inc., BioMerieux S.A., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., and Nova Biomedical Corporation

Recent Strategies Deployed in Point of Care Molecular Diagnostics Market

Partnerships, Collaboration and Agreements:

Mar-2023: QIAGEN N.V. formed a partnership with Servier, a global pharmaceutical group. The partnership aimed to develop and validate a real-time in vitro PCR test that can be used to detect IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates.

Apr-2023: BioMerieux S.A. partnered with Oxford Nanopore Technologies plc, a developer and seller of nanopore sequencing products for the direct, electronic analysis of single molecules. The partnership aimed to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.

Jan-2023: QIAGEN entered into a partnership with Helix, a California-based population genomics leader. Through this partnership, the company would leverage the Helix Laboratory Platform to offer innovative solutions for biopharmaceutical customers.

Feb-2021: Agilent Technologies formed a partnership with Mammoth Biosciences, a private biotechnology company. Through this partnership, the company aimed to offer a simple workflow to address the specific needs of high-throughput clinical testing laboratories.

Product Launch and Product Expansions:

Oct-2022: Roche revealed SARS-CoV-2 Rapid Antibody Test 2.0 for healthcare professionals to identify patients who have developed antibodies against the virus, indicating previous infection or vaccination.

Nov-2021: Roche unveiled cobas 5800 System, a new molecular laboratory instrument. The new system addresses challenges faced by laboratories from the increase in patient testing, reimbursement complexities, and the need for a more diverse testing menu while providing meaningful and timely results.

Acquisitions and Merger:

Aug-2022: Bio-Rad acquired Curiosity Diagnostics, a late-stage, pre-commercial platform company. This acquisition aimed at working closely to bring the latest generation of rapid PCR systems to market. Curiosity's PCR platform, PCR|ONE would offer a streamlined workflow as well as rapid turnaround times and is predicted to extend its reach beyond high-complexity labs into near-patient molecular diagnostics labs.

May-2022: BioMerieux completed the acquisition of Specific Diagnostics, a medical device startup that has developed in vitro diagnostic systems. The acquisition would enable the company to further develop its leadership in clinical microbiology and strengthen its fight against Antimicrobial Resistance.

May-2021: Roche took over GenMark Diagnostics, a leading vendor of multiplex molecular diagnostic solutions. This acquisition aimed to expand Roche's molecular diagnostics offerings to incorporate solutions with the capability to offer lifesaving information to patients, as well as their healthcare providers, rapidly.

Feb-2021: Thermo Fisher Scientific acquired Mesa Biotech, a healthcare test, and data company. The acquisition aimed at rapidly scaling manufacturing volume, driving cost efficiencies as well as bringing much-needed diagnostics to the market faster and at an expanded scale.

Scope of the Study

Market Segments covered in the Report:

By Product & Service

  • Assays & Kits
  • Instruments & Analyzers
  • Software & Services Surveillance & Monitoring

By End User

  • Physicians Offices
  • Hospitals & ICUs
  • Research Institutes
  • Others

By Technology

  • RT-PCR
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Others

By Application

  • Respiratory Diseases
  • Hospital-acquired Infections
  • Sexually Transmitted Diseases
  • Cancer
  • Hepatitis
  • Gastrointestinal Disorders
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Abbott Laboratories
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Qiagen N.V.
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • BioMerieux S.A.
  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific, Inc.
  • Nova Biomedical Corporation

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Point of Care Molecular Diagnostics Market, by Product & Service
    • 1.4.2 Global Point of Care Molecular Diagnostics Market, by End User
    • 1.4.3 Global Point of Care Molecular Diagnostics Market, by Technology
    • 1.4.4 Global Point of Care Molecular Diagnostics Market, by Application
    • 1.4.5 Global Point of Care Molecular Diagnostics Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Partnerships, Collaborations and Agreements
    • 3.2.2 Product Launches and Product Expansions
    • 3.2.3 Acquisition and Mergers
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)

Chapter 4. Global Point of Care Molecular Diagnostics Market by Product & Service

  • 4.1 Global Assays & Kits Market by Region
  • 4.2 Global Instruments & Analyzers Market by Region
  • 4.3 Global Software & Services Market by Region

Chapter 5. Global Point of Care Molecular Diagnostics Market by End User

  • 5.1 Global Physicians Offices Market by Region
  • 5.2 Global Hospitals & ICUs Market by Region
  • 5.3 Global Research Institutes Market by Region
  • 5.4 Global Others Market by Region

Chapter 6. Global Point of Care Molecular Diagnostics Market by Technology

  • 6.1 Global RT-PCR Market by Region
  • 6.2 Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market by Region
  • 6.3 Global Others Market by Region

Chapter 7. Global Point of Care Molecular Diagnostics Market by Application

  • 7.1 Global Respiratory Diseases Market by Region
  • 7.2 Global Hospital-acquired Infections Market by Region
  • 7.3 Global Sexually Transmitted Diseases Market by Region
  • 7.4 Global Cancer Market by Region
  • 7.5 Global Hepatitis Market by Region
  • 7.6 Global Gastrointestinal Disorders Market by Region
  • 7.7 Global Others Market by Region

Chapter 8. Global Point of Care Molecular Diagnostics Market by Region

  • 8.1 North America Point of Care Molecular Diagnostics Market
    • 8.1.1 North America Point of Care Molecular Diagnostics Market by Product & Service
      • 8.1.1.1 North America Assays & Kits Market by Country
      • 8.1.1.2 North America Instruments & Analyzers Market by Country
      • 8.1.1.3 North America Software & Services Market by Country
    • 8.1.2 North America Point of Care Molecular Diagnostics Market by End User
      • 8.1.2.1 North America Physicians Offices Market by Country
      • 8.1.2.2 North America Hospitals & ICUs Market by Country
      • 8.1.2.3 North America Research Institutes Market by Country
      • 8.1.2.4 North America Others Market by Country
    • 8.1.3 North America Point of Care Molecular Diagnostics Market by Technology
      • 8.1.3.1 North America RT-PCR Market by Country
      • 8.1.3.2 North America Isothermal Nucleic Acid Amplification Technology (INAAT) Market by Country
      • 8.1.3.3 North America Others Market by Country
    • 8.1.4 North America Point of Care Molecular Diagnostics Market by Application
      • 8.1.4.1 North America Respiratory Diseases Market by Country
      • 8.1.4.2 North America Hospital-acquired Infections Market by Country
      • 8.1.4.3 North America Sexually Transmitted Diseases Market by Country
      • 8.1.4.4 North America Cancer Market by Country
      • 8.1.4.5 North America Hepatitis Market by Country
      • 8.1.4.6 North America Gastrointestinal Disorders Market by Country
      • 8.1.4.7 North America Others Market by Country
    • 8.1.5 North America Point of Care Molecular Diagnostics Market by Country
      • 8.1.5.1 US Point of Care Molecular Diagnostics Market
        • 8.1.5.1.1 US Point of Care Molecular Diagnostics Market by Product & Service
        • 8.1.5.1.2 US Point of Care Molecular Diagnostics Market by End User
        • 8.1.5.1.3 US Point of Care Molecular Diagnostics Market by Technology
        • 8.1.5.1.4 US Point of Care Molecular Diagnostics Market by Application
      • 8.1.5.2 Canada Point of Care Molecular Diagnostics Market
        • 8.1.5.2.1 Canada Point of Care Molecular Diagnostics Market by Product & Service
        • 8.1.5.2.2 Canada Point of Care Molecular Diagnostics Market by End User
        • 8.1.5.2.3 Canada Point of Care Molecular Diagnostics Market by Technology
        • 8.1.5.2.4 Canada Point of Care Molecular Diagnostics Market by Application
      • 8.1.5.3 Mexico Point of Care Molecular Diagnostics Market
        • 8.1.5.3.1 Mexico Point of Care Molecular Diagnostics Market by Product & Service
        • 8.1.5.3.2 Mexico Point of Care Molecular Diagnostics Market by End User
        • 8.1.5.3.3 Mexico Point of Care Molecular Diagnostics Market by Technology
        • 8.1.5.3.4 Mexico Point of Care Molecular Diagnostics Market by Application
      • 8.1.5.4 Rest of North America Point of Care Molecular Diagnostics Market
        • 8.1.5.4.1 Rest of North America Point of Care Molecular Diagnostics Market by Product & Service
        • 8.1.5.4.2 Rest of North America Point of Care Molecular Diagnostics Market by End User
        • 8.1.5.4.3 Rest of North America Point of Care Molecular Diagnostics Market by Technology
        • 8.1.5.4.4 Rest of North America Point of Care Molecular Diagnostics Market by Application
  • 8.2 Europe Point of Care Molecular Diagnostics Market
    • 8.2.1 Europe Point of Care Molecular Diagnostics Market by Product & Service
      • 8.2.1.1 Europe Assays & Kits Market by Country
      • 8.2.1.2 Europe Instruments & Analyzers Market by Country
      • 8.2.1.3 Europe Software & Services Market by Country
    • 8.2.2 Europe Point of Care Molecular Diagnostics Market by End User
      • 8.2.2.1 Europe Physicians Offices Market by Country
      • 8.2.2.2 Europe Hospitals & ICUs Market by Country
      • 8.2.2.3 Europe Research Institutes Market by Country
      • 8.2.2.4 Europe Others Market by Country
    • 8.2.3 Europe Point of Care Molecular Diagnostics Market by Technology
      • 8.2.3.1 Europe RT-PCR Market by Country
      • 8.2.3.2 Europe Isothermal Nucleic Acid Amplification Technology (INAAT) Market by Country
      • 8.2.3.3 Europe Others Market by Country
    • 8.2.4 Europe Point of Care Molecular Diagnostics Market by Application
      • 8.2.4.1 Europe Respiratory Diseases Market by Country
      • 8.2.4.2 Europe Hospital-acquired Infections Market by Country
      • 8.2.4.3 Europe Sexually Transmitted Diseases Market by Country
      • 8.2.4.4 Europe Cancer Market by Country
      • 8.2.4.5 Europe Hepatitis Market by Country
      • 8.2.4.6 Europe Gastrointestinal Disorders Market by Country
      • 8.2.4.7 Europe Others Market by Country
    • 8.2.5 Europe Point of Care Molecular Diagnostics Market by Country
      • 8.2.5.1 Germany Point of Care Molecular Diagnostics Market
        • 8.2.5.1.1 Germany Point of Care Molecular Diagnostics Market by Product & Service
        • 8.2.5.1.2 Germany Point of Care Molecular Diagnostics Market by End User
        • 8.2.5.1.3 Germany Point of Care Molecular Diagnostics Market by Technology
        • 8.2.5.1.4 Germany Point of Care Molecular Diagnostics Market by Application
      • 8.2.5.2 UK Point of Care Molecular Diagnostics Market
        • 8.2.5.2.1 UK Point of Care Molecular Diagnostics Market by Product & Service
        • 8.2.5.2.2 UK Point of Care Molecular Diagnostics Market by End User
        • 8.2.5.2.3 UK Point of Care Molecular Diagnostics Market by Technology
        • 8.2.5.2.4 UK Point of Care Molecular Diagnostics Market by Application
      • 8.2.5.3 France Point of Care Molecular Diagnostics Market
        • 8.2.5.3.1 France Point of Care Molecular Diagnostics Market by Product & Service
        • 8.2.5.3.2 France Point of Care Molecular Diagnostics Market by End User
        • 8.2.5.3.3 France Point of Care Molecular Diagnostics Market by Technology
        • 8.2.5.3.4 France Point of Care Molecular Diagnostics Market by Application
      • 8.2.5.4 Russia Point of Care Molecular Diagnostics Market
        • 8.2.5.4.1 Russia Point of Care Molecular Diagnostics Market by Product & Service
        • 8.2.5.4.2 Russia Point of Care Molecular Diagnostics Market by End User
        • 8.2.5.4.3 Russia Point of Care Molecular Diagnostics Market by Technology
        • 8.2.5.4.4 Russia Point of Care Molecular Diagnostics Market by Application
      • 8.2.5.5 Spain Point of Care Molecular Diagnostics Market
        • 8.2.5.5.1 Spain Point of Care Molecular Diagnostics Market by Product & Service
        • 8.2.5.5.2 Spain Point of Care Molecular Diagnostics Market by End User
        • 8.2.5.5.3 Spain Point of Care Molecular Diagnostics Market by Technology
        • 8.2.5.5.4 Spain Point of Care Molecular Diagnostics Market by Application
      • 8.2.5.6 Italy Point of Care Molecular Diagnostics Market
        • 8.2.5.6.1 Italy Point of Care Molecular Diagnostics Market by Product & Service
        • 8.2.5.6.2 Italy Point of Care Molecular Diagnostics Market by End User
        • 8.2.5.6.3 Italy Point of Care Molecular Diagnostics Market by Technology
        • 8.2.5.6.4 Italy Point of Care Molecular Diagnostics Market by Application
      • 8.2.5.7 Rest of Europe Point of Care Molecular Diagnostics Market
        • 8.2.5.7.1 Rest of Europe Point of Care Molecular Diagnostics Market by Product & Service
        • 8.2.5.7.2 Rest of Europe Point of Care Molecular Diagnostics Market by End User
        • 8.2.5.7.3 Rest of Europe Point of Care Molecular Diagnostics Market by Technology
        • 8.2.5.7.4 Rest of Europe Point of Care Molecular Diagnostics Market by Application
  • 8.3 Asia Pacific Point of Care Molecular Diagnostics Market
    • 8.3.1 Asia Pacific Point of Care Molecular Diagnostics Market by Product & Service
      • 8.3.1.1 Asia Pacific Assays & Kits Market by Country
      • 8.3.1.2 Asia Pacific Instruments & Analyzers Market by Country
      • 8.3.1.3 Asia Pacific Software & Services Market by Country
    • 8.3.2 Asia Pacific Point of Care Molecular Diagnostics Market by End User
      • 8.3.2.1 Asia Pacific Physicians Offices Market by Country
      • 8.3.2.2 Asia Pacific Hospitals & ICUs Market by Country
      • 8.3.2.3 Asia Pacific Research Institutes Market by Country
      • 8.3.2.4 Asia Pacific Others Market by Country
    • 8.3.3 Asia Pacific Point of Care Molecular Diagnostics Market by Technology
      • 8.3.3.1 Asia Pacific RT-PCR Market by Country
      • 8.3.3.2 Asia Pacific Isothermal Nucleic Acid Amplification Technology (INAAT) Market by Country
      • 8.3.3.3 Asia Pacific Others Market by Country
    • 8.3.4 Asia Pacific Point of Care Molecular Diagnostics Market by Application
      • 8.3.4.1 Asia Pacific Respiratory Diseases Market by Country
      • 8.3.4.2 Asia Pacific Hospital-acquired Infections Market by Country
      • 8.3.4.3 Asia Pacific Sexually Transmitted Diseases Market by Country
      • 8.3.4.4 Asia Pacific Cancer Market by Country
      • 8.3.4.5 Asia Pacific Hepatitis Market by Country
      • 8.3.4.6 Asia Pacific Gastrointestinal Disorders Market by Country
      • 8.3.4.7 Asia Pacific Others Market by Country
    • 8.3.5 Asia Pacific Point of Care Molecular Diagnostics Market by Country
      • 8.3.5.1 China Point of Care Molecular Diagnostics Market
        • 8.3.5.1.1 China Point of Care Molecular Diagnostics Market by Product & Service
        • 8.3.5.1.2 China Point of Care Molecular Diagnostics Market by End User
        • 8.3.5.1.3 China Point of Care Molecular Diagnostics Market by Technology
        • 8.3.5.1.4 China Point of Care Molecular Diagnostics Market by Application
      • 8.3.5.2 Japan Point of Care Molecular Diagnostics Market
        • 8.3.5.2.1 Japan Point of Care Molecular Diagnostics Market by Product & Service
        • 8.3.5.2.2 Japan Point of Care Molecular Diagnostics Market by End User
        • 8.3.5.2.3 Japan Point of Care Molecular Diagnostics Market by Technology
        • 8.3.5.2.4 Japan Point of Care Molecular Diagnostics Market by Application
      • 8.3.5.3 India Point of Care Molecular Diagnostics Market
        • 8.3.5.3.1 India Point of Care Molecular Diagnostics Market by Product & Service
        • 8.3.5.3.2 India Point of Care Molecular Diagnostics Market by End User
        • 8.3.5.3.3 India Point of Care Molecular Diagnostics Market by Technology
        • 8.3.5.3.4 India Point of Care Molecular Diagnostics Market by Application
      • 8.3.5.4 South Korea Point of Care Molecular Diagnostics Market
        • 8.3.5.4.1 South Korea Point of Care Molecular Diagnostics Market by Product & Service
        • 8.3.5.4.2 South Korea Point of Care Molecular Diagnostics Market by End User
        • 8.3.5.4.3 South Korea Point of Care Molecular Diagnostics Market by Technology
        • 8.3.5.4.4 South Korea Point of Care Molecular Diagnostics Market by Application
      • 8.3.5.5 Singapore Point of Care Molecular Diagnostics Market
        • 8.3.5.5.1 Singapore Point of Care Molecular Diagnostics Market by Product & Service
        • 8.3.5.5.2 Singapore Point of Care Molecular Diagnostics Market by End User
        • 8.3.5.5.3 Singapore Point of Care Molecular Diagnostics Market by Technology
        • 8.3.5.5.4 Singapore Point of Care Molecular Diagnostics Market by Application
      • 8.3.5.6 Malaysia Point of Care Molecular Diagnostics Market
        • 8.3.5.6.1 Malaysia Point of Care Molecular Diagnostics Market by Product & Service
        • 8.3.5.6.2 Malaysia Point of Care Molecular Diagnostics Market by End User
        • 8.3.5.6.3 Malaysia Point of Care Molecular Diagnostics Market by Technology
        • 8.3.5.6.4 Malaysia Point of Care Molecular Diagnostics Market by Application
      • 8.3.5.7 Rest of Asia Pacific Point of Care Molecular Diagnostics Market
        • 8.3.5.7.1 Rest of Asia Pacific Point of Care Molecular Diagnostics Market by Product & Service
        • 8.3.5.7.2 Rest of Asia Pacific Point of Care Molecular Diagnostics Market by End User
        • 8.3.5.7.3 Rest of Asia Pacific Point of Care Molecular Diagnostics Market by Technology
        • 8.3.5.7.4 Rest of Asia Pacific Point of Care Molecular Diagnostics Market by Application
  • 8.4 LAMEA Point of Care Molecular Diagnostics Market
    • 8.4.1 LAMEA Point of Care Molecular Diagnostics Market by Product & Service
      • 8.4.1.1 LAMEA Assays & Kits Market by Country
      • 8.4.1.2 LAMEA Instruments & Analyzers Market by Country
      • 8.4.1.3 LAMEA Software & Services Market by Country
    • 8.4.2 LAMEA Point of Care Molecular Diagnostics Market by End User
      • 8.4.2.1 LAMEA Physicians Offices Market by Country
      • 8.4.2.2 LAMEA Hospitals & ICUs Market by Country
      • 8.4.2.3 LAMEA Research Institutes Market by Country
      • 8.4.2.4 LAMEA Others Market by Country
    • 8.4.3 LAMEA Point of Care Molecular Diagnostics Market by Technology
      • 8.4.3.1 LAMEA RT-PCR Market by Country
      • 8.4.3.2 LAMEA Isothermal Nucleic Acid Amplification Technology (INAAT) Market by Country
      • 8.4.3.3 LAMEA Others Market by Country
    • 8.4.4 LAMEA Point of Care Molecular Diagnostics Market by Application
      • 8.4.4.1 LAMEA Respiratory Diseases Market by Country
      • 8.4.4.2 LAMEA Hospital-acquired Infections Market by Country
      • 8.4.4.3 LAMEA Sexually Transmitted Diseases Market by Country
      • 8.4.4.4 LAMEA Cancer Market by Country
      • 8.4.4.5 LAMEA Hepatitis Market by Country
      • 8.4.4.6 LAMEA Gastrointestinal Disorders Market by Country
      • 8.4.4.7 LAMEA Others Market by Country
    • 8.4.5 LAMEA Point of Care Molecular Diagnostics Market by Country
      • 8.4.5.1 Brazil Point of Care Molecular Diagnostics Market
        • 8.4.5.1.1 Brazil Point of Care Molecular Diagnostics Market by Product & Service
        • 8.4.5.1.2 Brazil Point of Care Molecular Diagnostics Market by End User
        • 8.4.5.1.3 Brazil Point of Care Molecular Diagnostics Market by Technology
        • 8.4.5.1.4 Brazil Point of Care Molecular Diagnostics Market by Application
      • 8.4.5.2 Argentina Point of Care Molecular Diagnostics Market
        • 8.4.5.2.1 Argentina Point of Care Molecular Diagnostics Market by Product & Service
        • 8.4.5.2.2 Argentina Point of Care Molecular Diagnostics Market by End User
        • 8.4.5.2.3 Argentina Point of Care Molecular Diagnostics Market by Technology
        • 8.4.5.2.4 Argentina Point of Care Molecular Diagnostics Market by Application
      • 8.4.5.3 UAE Point of Care Molecular Diagnostics Market
        • 8.4.5.3.1 UAE Point of Care Molecular Diagnostics Market by Product & Service
        • 8.4.5.3.2 UAE Point of Care Molecular Diagnostics Market by End User
        • 8.4.5.3.3 UAE Point of Care Molecular Diagnostics Market by Technology
        • 8.4.5.3.4 UAE Point of Care Molecular Diagnostics Market by Application
      • 8.4.5.4 Saudi Arabia Point of Care Molecular Diagnostics Market
        • 8.4.5.4.1 Saudi Arabia Point of Care Molecular Diagnostics Market by Product & Service
        • 8.4.5.4.2 Saudi Arabia Point of Care Molecular Diagnostics Market by End User
        • 8.4.5.4.3 Saudi Arabia Point of Care Molecular Diagnostics Market by Technology
        • 8.4.5.4.4 Saudi Arabia Point of Care Molecular Diagnostics Market by Application
      • 8.4.5.5 South Africa Point of Care Molecular Diagnostics Market
        • 8.4.5.5.1 South Africa Point of Care Molecular Diagnostics Market by Product & Service
        • 8.4.5.5.2 South Africa Point of Care Molecular Diagnostics Market by End User
        • 8.4.5.5.3 South Africa Point of Care Molecular Diagnostics Market by Technology
        • 8.4.5.5.4 South Africa Point of Care Molecular Diagnostics Market by Application
      • 8.4.5.6 Nigeria Point of Care Molecular Diagnostics Market
        • 8.4.5.6.1 Nigeria Point of Care Molecular Diagnostics Market by Product & Service
        • 8.4.5.6.2 Nigeria Point of Care Molecular Diagnostics Market by End User
        • 8.4.5.6.3 Nigeria Point of Care Molecular Diagnostics Market by Technology
        • 8.4.5.6.4 Nigeria Point of Care Molecular Diagnostics Market by Application
      • 8.4.5.7 Rest of LAMEA Point of Care Molecular Diagnostics Market
        • 8.4.5.7.1 Rest of LAMEA Point of Care Molecular Diagnostics Market by Product & Service
        • 8.4.5.7.2 Rest of LAMEA Point of Care Molecular Diagnostics Market by End User
        • 8.4.5.7.3 Rest of LAMEA Point of Care Molecular Diagnostics Market by Technology
        • 8.4.5.7.4 Rest of LAMEA Point of Care Molecular Diagnostics Market by Application

Chapter 9. Company Profiles

  • 9.1 Abbott Laboratories
    • 9.1.1 Company Overview
    • 9.1.2 Financial Analysis
    • 9.1.3 Segmental and Regional Analysis
    • 9.1.4 Research & Development Expense
    • 9.1.5 SWOT Analysis
  • 9.2 Bayer AG
    • 9.2.1 Company Overview
    • 9.2.2 Financial Analysis
    • 9.2.3 Segmental and Regional Analysis
    • 9.2.4 Research & Development Expense
    • 9.2.5 SWOT Analysis
  • 9.3 Thermo Fisher Scientific, Inc.
    • 9.3.1 Company Overview
    • 9.3.2 Financial Analysis
    • 9.3.3 Segmental and Regional Analysis
    • 9.3.4 Research & Development Expenses
    • 9.3.5 Recent strategies and developments:
      • 9.3.5.1 Acquisition and Mergers:
    • 9.3.6 SWOT Analysis
  • 9.4 F. Hoffmann-La Roche Ltd.
    • 9.4.1 Company Overview
    • 9.4.2 Financial Analysis
    • 9.4.3 Segmental and Regional Analysis
    • 9.4.4 Research & Development Expense
    • 9.4.5 Recent strategies and developments:
      • 9.4.5.1 Partnerships, Collaborations, and Agreements:
      • 9.4.5.2 Product Launches and Product Expansions:
      • 9.4.5.3 Acquisition and Mergers:
  • 9.5 BioMerieux S.A.
    • 9.5.1 Company Overview
    • 9.5.2 Financial Analysis
    • 9.5.3 Segmental and Regional Analysis
    • 9.5.4 Research & Development Expenses
    • 9.5.5 Recent strategies and developments:
      • 9.5.5.1 Partnerships, Collaborations, and Agreements:
      • 9.5.5.2 Acquisition and Mergers:
  • 9.6 Qiagen N.V.
    • 9.6.1 Company Overview
    • 9.6.2 Financial Analysis
    • 9.6.3 Regional Analysis
    • 9.6.4 Research & Development Expense
    • 9.6.5 Recent strategies and developments:
      • 9.6.5.1 Partnerships, Collaborations, and Agreements:
  • 9.7 Danaher Corporation
    • 9.7.1 Company Overview
    • 9.7.2 Financial Analysis
    • 9.7.3 Segmental and Regional Analysis
    • 9.7.4 Research & Development Expense
  • 9.8 Bio-Rad laboratories, Inc.
    • 9.8.1 Company Overview
    • 9.8.2 Financial Analysis
    • 9.8.3 Segmental and Regional Analysis
    • 9.8.4 Research & Development Expenses
    • 9.8.5 Recent strategies and developments:
      • 9.8.5.1 Acquisition and Mergers:
  • 9.9 Agilent Technologies, Inc.
    • 9.9.1 Company Overview
    • 9.9.2 Financial Analysis
    • 9.9.3 Segmental and Regional Analysis
    • 9.9.4 Research & Development Expense
    • 9.9.5 Recent strategies and developments:
      • 9.9.5.1 Partnerships, Collaborations, and Agreements:
  • 9.10. Nova Biomedical Corporation
    • 9.10.1 Company Overview
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제